Supplementary Materials and Methods and Supplementary Figures 1-6 from The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate–Lactate Exchange in BRAF-Mutant Human Melanoma Cells

Le résumé fourni par la source

Supplementary material and methods: -Western blotting -Quantitative real-time PCR (qRT-PCR) -Reactive oxygen species (ROS) production assay -NMR metabolic analyses of cells -NMR data acquisition and processing -Measurements of ADP/ATP ratios Supplementary Figures: -Figure S1: Cell proliferation is not significantly different using 25 mM or 5 mM glucose medium after 24h or 48h of treatment. -Figrue S2: BRAF mutant cells maintain their bioenergetics level under BRAF inhibition. -Figure S3: BRAF mutant WM266.4 cells show increased ROS levels under BRAF inhibition. -Figure S4: Changes in cell counts in WM266.4 and SKMEL28 control and treated samples in the 4 nutrient-restricted conditions. -Figure S5: Changes in cell cycle distribution in control and vemurafenib-treated WM266.4 cell samples in the 4 different nutrient conditions. -Figure S6: Cell lipid content detection by 1H NMR.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.